Subscribe
Following the discontinuation of ALLO-647 due to a treatment-related death, Allogene will move forward with a streamlined outpatient regimen aimed at accelerating enrollment and regulatory review in the Phase II ALPHA3 trial (NCT06500273).
Flawless but Fake? The Ethics of AI Social Media Influencers in Pharmaceutical Advertising
Bridging Vision and Value: How Target Product Profiles and Value Evidence Archetypes Must Align for Market Access Success
From Science to Sales: Leveraging Medical Affairs for Commercial Triumph
HEOR: From Proving Product Value to Proving Its Own Worth
259 Prospect Plains Rd, Bldg H Cranbury, NJ 08512
609-716-7777
